肝细胞生长因子测定在膀胱癌诊疗中的临床应用  

Application Study of the Level of Hepatocyte Growth Factor on the Diagnosis and Treatment of Bladder Carcinoma

作　　者：马增煌[1] 陈丽峰[1] 胡芳[1] 潘卫斌[2] 顾磊[3] 

机构地区：[1]黄石市中心医院检验科,湖北黄石435000 [2]黄石市中心医院泌尿外科,湖北黄石435000 [3]黄石市中心医院病理科,湖北黄石435000

出　　处：《现代检验医学杂志》2008年第1期24-25,共2页Journal of Modern Laboratory Medicine

基　　金：湖北省科技攻关项目(6AA301C46)

摘　　要：目的该实验旨在探讨肝细胞生长因子(HGF)在膀胱癌患者中的分布水平,为进一步对膀胱癌的临床治疗提供理论依据。方法用ELISA法测定膀胱癌术前患者血清HGF水平,同时选取正常对照同步测定。结果高、中、低分化组和对照组血清HGF水平分别为(4.32±0.58)×10-6,(5.67±0.63)×10-6,(6.81±0.42)×10-6,(1.96±0.23)×10-6mol/L。结论该实验表明,血清HGF水平的测定,可以作为判断膀胱癌分化程度及预后的重要指标。Objective To explore the level of plasma hepatocyte growth factor（HGF） in the bladder carcinoma patients in order to provide the basis in theory for clinical treatment. Methods The plasma HGF in the preoperative patients with bladder carcinoma was measured by ELISA and in the control groups at the same time. Results The concentration of HGF in well-differentiated ,moderately differentiated ,poorly differentiated and control groups was （4.32±0.58）×10^-6, （5.67±0.63）×10^-6, （6.81 ±0.42）×10^-6 and （1.96±0.23）×10^-6 mol/L respectively. Conclusion The level of plasma HGF may be a important index to judge differentiation and prognosis in the bladder carcinoma.

关 键 词：肝细胞生长因子 膀胱癌 肿瘤 

分 类 号：R730.43[医药卫生—肿瘤] R737.14[医药卫生—临床医学]